根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《深圳证券交易所上市公司自律监管指引第 2 号－－创业板上市公司规范 运作》等相关规定，乐普（北京）医疗器械股份有限公司（以下简称：公司）董 事会将 2023 年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 证券代码：300003 证券简称：乐普医疗 公告编号：2024-031 乐普（北京）医疗器械股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 （一）境内募集资金基本情况 经中国证券监督管理委员会证监许可[2021] 741 号《关于同意乐普（北京） 医疗器械股份有限公司向不特定对象发行可转债注册的批复》核准，公司于 2021 年 3 月向社会公开发行可转换公司债券 1,638.00 万张，每张面值为人民币 100 元，募集资金总额为人民币 163,800.00 万元。主承销商海通证券根据与本公司 签定的承销协议，将募集资金总额在直接扣除承销及保荐费 1,390.75 万元（不 含税）后，将余款 162, ...

Financial Performance - The company's revenue for Q1 2024 was ¥1,922,028,839.15, a decrease of 21.14% compared to the same period last year[4] - Net profit attributable to shareholders was ¥481,871,134.58, down 19.27% year-on-year[4] - The revenue from the medical device segment was ¥885,619,800, a year-on-year decrease of 18.69%[8] - The cardiovascular intervention business generated revenue of ¥438,018,100, a year-on-year increase of 5.80%[8] - The pharmaceutical segment's revenue was ¥792,915,700, down 15.69% year-on-year[9] - Total operating revenue for the current period is ¥1,922,028,839.15, a decrease of 21.1% from ¥2,437,202,386.92 in the previous period[23] - Net profit for the current period is ¥492,760,543.46, a decline of 20.3% compared to ¥618,318,467.79 in the previous period[25] - Basic earnings per share for the current period is ¥0.2594, down from ¥0.3205 in the previous period[25] - Total comprehensive income for the current period is ¥483,962,303.22, a decrease from ¥657,211,412.12 in the previous period[25] Cash Flow and Assets - The net cash flow from operating activities was ¥141,518,257.63, an increase of 205.45% compared to the previous year[4] - Cash flow from operating activities for the current period is ¥141,518,257.63, compared to a negative cash flow of -¥134,203,435.01 in the previous period[26] - Cash received from sales of goods and services is ¥1,636,352,953.22, down from ¥2,221,855,789.57 in the previous period[26] - The company's total assets at the end of the reporting period were ¥25,508,525,579.77, an increase of 1.94% from the end of the previous year[4] - The company's total liabilities were CNY 7.50 billion, slightly down from CNY 7.52 billion at the beginning of the period[22] - The company’s total equity reached CNY 18.01 billion, up from CNY 17.50 billion at the beginning of the period[22] - The cash and cash equivalents decreased to CNY 4.13 billion from CNY 4.22 billion at the beginning of the period[20] - The company’s inventory decreased to CNY 2.22 billion from CNY 2.29 billion at the beginning of the period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 91,316[12] - The largest shareholder, China Shipbuilding Industry Group Company, holds 12.98% of shares, totaling 244,063,788 shares[12] - The second-largest shareholder, Pu Zhongjie, holds 12.13% of shares, totaling 228,074,749 shares, with 171,056,062 shares under lock-up[12] - WP Medical Technologies, Inc. holds 6.59% of shares, totaling 123,968,600 shares, with 92,976,450 shares under lock-up[12] - The top ten shareholders account for a significant portion of the company's equity, with the largest ten shareholders holding a combined total of 63.88%[12] - The report indicates that there are no changes in the number of restricted shares for major shareholders during the reporting period[16] - The total number of restricted shares held by Pu Zhongjie remains at 171,056,062 shares, with no shares released during the period[16] Research and Development - The company has not disclosed any new product developments or technological advancements in this report[17] - The company received NMPA approval for its self-developed coronary intravascular shockwave catheter, obtaining Class III medical device registration with certificate number 20243010074[18] - The company also obtained NMPA approval for its self-developed coronary papillary balloon dilation catheter, with registration certificate number 20243030105[18] - The company's subsidiary, Lepu Pharmaceutical Technology Co., Ltd., received NMPA approval for its self-developed Oseltamivir phosphate dry suspension, with drug approval number H20243080[18] - The company’s subsidiaries participated in the centralized procurement bidding for Amoxicillin and other drugs, with plans to win bids for Clopidogrel hydrogen sulfate tablets, Atorvastatin calcium tablets, and Rosuvastatin calcium tablets[19] - The company’s subsidiary, Shanghai Minwei Biotechnology Co., Ltd., is conducting two Phase II clinical trials for the self-developed GLP-1/GCGR/GIP-Fc fusion protein MWN101 for the treatment of type 2 diabetes and obesity, with the first subject dosed successfully[19] Investment Activities - The company reported a net investment loss of ¥4,292,600, a decrease of 80.07% compared to the previous year[9] - Investment income for the current period shows a loss of ¥4,292,647.74, an improvement from a loss of ¥21,542,984.71 in the previous period[23] - Total cash inflow from investment activities was approximately CNY 210.29 million, a decrease from CNY 289.84 million in the previous period[27] - Cash outflow from investment activities totaled CNY 490.31 million, slightly down from CNY 502.25 million year-over-year[27] - Net cash flow from investment activities was negative CNY 280.02 million, compared to negative CNY 212.41 million in the prior year[27] Financing Activities - Cash inflow from financing activities amounted to CNY 646.68 million, a slight decrease from CNY 656.42 million[27] - Net cash flow from financing activities was negative CNY 52.06 million, contrasting with a positive CNY 250.48 million in the same period last year[27] - The net increase in cash and cash equivalents was negative CNY 188.90 million, compared to negative CNY 138.75 million previously[27] - The ending balance of cash and cash equivalents was CNY 3.91 billion, down from CNY 5.17 billion year-over-year[27] - The company reported a significant increase in cash paid for fixed assets, intangible assets, and other long-term assets, totaling CNY 144.13 million, compared to CNY 210.65 million in the previous period[27] - Cash received from borrowings was CNY 634.09 million, slightly up from CNY 617.00 million[27] Audit and Reporting - The company’s first quarter report was not audited[27] - There is no mention of market expansion or mergers and acquisitions in the current report[17] - The report does not provide specific future outlook or performance guidance for the upcoming quarters[17]

证券代码：300003 证券简称：乐普医疗 公告编号：2024-040 乐普（北京）医疗器械股份有限公司 关于召开2023年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确，完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《公司法》和《公司章程》的有关规定，经乐普（北京）医疗器械股份 有限公司（以下简称"乐普医疗"或"公司"）第六届董事会第七次会议审议通 过，决定召开2023年年度股东大会，现将会议有关事项向全体股东通知如下： 一、本次股东大会召开的基本情况 1、会议届次：2023年年度股东大会 2、会议召集人：乐普（北京）医疗器械股份有限公司董事会 3、会议召开的合法、合规性：经本公司第六届董事会第七次会议审议通 过，决定召开2023年年度股东大会，召集程序符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 4、会议召开时间： （1）现场会议时间：2024年5月15日（星期三）下午14:00 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为2024年5月15日 上午9:15－9:25、9:30-11:30，13:00-15:00； 通过深圳证 ...

乐普（北京）医疗器械股份有限公司 公司章程 乐普（北京）医疗器械股份有限公司 章 程 二零二四年四月 | 第一章 | 总 则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股 份 5 | | 第一节 | 股东持股情况 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东大会 9 | | 第一节 | 股东 9 | | 第二节 | 股东大会的一般规定 11 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 16 | | 第五节 | 股东大会的召开 18 | | 第六节 | 股东大会的表决和决议 21 | | 第五章 | 董事会 26 | | 第一节 | 董事 26 | | 第二节 | 独立董事 29 | | 第三节 | 董事会 31 | | 第六章 | 高级管理人员 37 | | 第七章 | 监事会 39 | | 第一节 | 监事 39 | | 第二节 | 监事会 40 | | 第三节 | 监事会决议 42 | | --- | --- | | 第八章 | 财务会计制度、利润分配和 ...

乐普（北京）医疗器械股份有限公司 独立董事述职报告 乐普（北京）医疗器械股份有限公司 独立董事 2023 年度述职报告 （甘亮） 作为乐普（北京）医疗器械股份有限公司（以下简称"公司"）的独立董事， 本人 2023 年度任职期间严格按照《公司法》《证券法》《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关法律法规和《公司章程》《独立董事工作制度》等公司相关的规 定和要求，忠实履行独立董事的职责，充分发挥独立董事独立性和专业性的作用， 维护了全体股东尤其是中小股东的合法权益。现将本人 2023 年度履行独立董事 职责情况向各位董事汇报如下： 一、2023 年度出席董事会和列席股东大会情况 2023 年度，本着勤勉尽责的态度，本人积极参加公司召开的董事会和股东 大会，认真审阅会议材料，积极参与各项议案的讨论，为董事会的正确决策发挥 了积极的作用。 担保情况的独立意见》，认为报告期内公司不存在控股股东、实际控制人及其他 关联方占用公司资金的情况也不存在以前年度发生并累积至 2022 年 12 月 31 日 的控股股东、实际控制人及其他关联方占用公司资金的 ...

乐普（北京）医疗器械股份有限公司 董事会审计委员会规则 乐普（北京）医疗器械股份有限公司 董事会审计委员会规则 二零二四年四月 | 第一章 | 总则 2 | | --- | --- | | 第二章 | 人员组成 2 | | 第三章 | 职责权限 2 | | 第四章 | 议事规则 4 | | 第五章 | 附则 6 | 乐普（北京）医疗器械股份有限公司 董事会审计委员会规则 第一章 总则 第一条 为强化乐普（北京）医疗器械股份有限公司（以下简称"公司"） 董事会对经营层的有效监督，进一步完善公司法人治理结构，根据《中华人民共 和国公司法》、《上市公司治理准则》、《乐普（北京）医疗器械股份有限公司章程》 （以下简称"《公司章程》"）及其他有关规定，特制定本规则。 第二条 董事会审计委员会是董事会按照股东大会决议设立的专门工作 机构，主要负责公司内、外部审计的沟通、监督和核查工作。 第二章 人员组成 第三条 审计委员会由三至五名董事组成，审计委员会委员应当为不在公 司担任高级管理人员的董事，其中独立董事占多数,且委员中至少有一名独立董 事为会计专业人士。 第四条 审计委员会委员由董事长、二分之一以上独立董事或者全体董 ...

乐普（北京）医疗器械股份有限公司 2023 年度监事会工作报告 证券代码：300003 证券简称：乐普医疗 公告编号：2024-024 乐普（北京）医疗器械股份有限公司 2023 年度监事会工作报告 2023 年，乐普（北京）医疗器械股份有限公司（以下简称"公司"或"乐 普医疗"）监事会依据《公司法》《证券法》等法律、法规、规范性文件以及《乐 普医疗公司章程》(以下简称"公司章程")、《监事会议事规则》的规定，本着 对公司和全体股东负责的原则，认真履行监督职责，通过列席董事会、出席股东 大会，对公司股东大会及董事会的召开程序和决策程序、董事会对股东大会决议 的执行情况、高级管理人员的履职情况、公司管理制度的执行情况、公司内部控 制情况、定期报告等重大事项的表决程序、公允性、合法性、合规性进行了监督 检查；认真了解核查公司生产经营活动、财务状况、内部控制运作情况，在维护 公司利益、股东权益及促进公司规范运作等方面发挥了积极作用。现将 2023 年 度公司监事会工作报告如下： 一、报告期内监事会日常工作情况 报告期内，公司监事会共召开了 6 次会议，监事会成员参加了全部会议，历 次会议的召集、提案、出席、议事、表 ...

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the medical device segment[7]. - The company's operating revenue for 2023 was ¥7,979,899,319.74, a decrease of 24.78% compared to ¥10,609,442,080.61 in 2022[13]. - The net profit attributable to shareholders for 2023 was ¥1,258,200,337.67, down 42.91% from ¥2,202,809,390.54 in 2022[13]. - The net profit after deducting non-recurring gains and losses was ¥1,123,116,336.93, a decline of 47.60% from ¥2,142,486,458.55 in 2022[13]. - The net cash flow from operating activities for 2023 was ¥990,359,814.31, a significant drop of 64.51% compared to ¥2,790,709,307.02 in 2022[13]. - The company reported a total revenue of CNY 797,989.93 million, a year-on-year decrease of 24.78%[79]. - Net profit attributable to shareholders was CNY 125,820.03 million, down 42.91% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 112,311.63 million, a decrease of 47.60%[79]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the Asia-Pacific region, aiming for a 20% increase in market share by 2025[7]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a target of completing at least two acquisitions by the end of 2024[7]. - The company is actively exploring international markets, enhancing its competitiveness and aiming for high-quality development in the global arena[28]. - The company is currently constructing production capacity in Malaysia to strengthen its market presence in Malaysia and surrounding Southeast Asian regions[35]. - The company plans to expand its product offerings in the diabetes treatment sector with the launch of a continuous glucose monitoring system[96]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers[152]. Research and Development - The company is investing 200 million CNY in R&D for innovative medical technologies over the next two years[7]. - The company has a rich R&D pipeline, continuously innovating in areas such as coronary intervention and structural heart disease[28]. - The total R&D investment for 2023 was approximately ¥1.24 billion, representing 15.56% of the operating revenue, an increase from 12.10% in 2022[97]. - The company has established an AI research institute to enhance the application of artificial intelligence in the medical field, with several products in various stages of clinical trials and registration[53]. - The company is enhancing its R&D capabilities to improve product development efficiency and increase the success rate of clinical trials and registrations[127]. Product Development and Innovation - New product launches are expected to contribute an additional 10% to the overall revenue in the next fiscal year[7]. - The company has several products in the pipeline, including drug-eluting balloons and biodegradable drug-eluting stents, expected to be commercialized between 2024 and 2026[31]. - The company is focusing on innovation in structural heart disease, with the RF-Lance® radiofrequency septal puncture system submitted for registration, enhancing the safety and success rate of cardiac interventions[41]. - The company has received regulatory approval for several innovative products, including the MemoSorb® biodegradable occluder and various catheter devices, which are expected to drive revenue growth[61][62]. - The company is developing innovative minimally invasive techniques for mitral valve interventions, addressing a significant market need with an estimated 7.5 million patients requiring intervention in China[94]. Sustainability and Environmental Initiatives - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 25% by 2025[7]. - The company has established compliance with various environmental discharge standards, including wastewater and air emissions[200]. - The company has implemented a self-monitoring plan for various pollutants, with specific monitoring frequencies for wastewater and air emissions[196]. - The company has made efforts to reduce carbon emissions, although specific measures and their effects were not detailed in the report[198]. - The company has invested CNY 3,600,000 in environmental governance and protection, and paid CNY 11,000 in environmental protection tax[198]. Governance and Shareholder Relations - The company aims to enhance governance and operational standards, ensuring the protection of shareholders' legal rights[132]. - The company emphasizes the importance of investor returns and aims to increase the proportion of cash dividends in the future[132]. - The company has established a performance evaluation and incentive system linking executive compensation to business performance[138]. - The company has maintained independence from its controlling shareholders in terms of operations, assets, and management[135]. - The company held three investor communication sessions in 2023, with a total of 379 participants from 261 institutions in April, 316 from 206 institutions in August, and 255 from 192 institutions in October[130]. Operational Efficiency and Challenges - The company is focused on improving operational efficiency and product quality to maintain a competitive edge in the healthcare market[71]. - The company faces risks from volume-based procurement policies affecting high-value medical consumables and drugs, which may lead to price reductions and impact revenue and profit[125]. - The company is facing increased competition in the medical device and pharmaceutical sectors, necessitating dynamic adjustments to R&D processes and cost control measures[127]. - The company has implemented a structured management system to address the challenges of group management and ensure healthy and safe overall operations[129]. - The company has successfully obtained certification for rapid thrombectomy devices in the peripheral intervention field as of the reporting date[37].

证券代码：300003 证券简称：乐普医疗 公告编号：2024-026 乐普（北京）医疗器械股份有限公司 关于 2023 年度利润分配预案的公告 一、利润分配预案基本情况 1、利润分配预案的具体内容 经立信会计师事务所（特殊普通合伙）审计，2023 年公司实现归属于上市 公司股东的净利润 1,258,200,337.67 元，母公司实现净利润 684,986,398.67 元。 根据《公司法》和《公司章程》的有关规定，按 2023 年度母公司净利润的 10% 提取法定公积金 68,498,639.87 元 ， 本 年 度 可 供 股 东 分 配 的 利 润 为 616,487,758.80 元。 公司拟以 2024 年度权益分派方案未来实施时股权登记日的总股本，扣减已 回购股份后的股本为基数，按每 10 股派发现金红利 3.3141 元（含税），剩余未 分配利润结转下一年度。 截至 2024 年 3 月 29 日，公司总股本为 1,880,610,488 股，已通过股份回 购证券专用账户以集中竞价交易方式累计回购公司股份 28,235,700 股，占公司 总股本的 1.5014%。按公司总股本 1,880,6 ...

第六届董事会独立董事专门会议2024年第一次会议 会议决议 乐普（北京）医疗器械股份有限公司 第六届董事会独立董事专门会议2024年第一次会议决议 乐普（北京）医疗器械股份有限公司（以下简称：公司）第六届董事会独立 董事专门会议第一次会议于2024年4月15日在公司会议室以现场会议方式召开。 本次会议通知及相关材料于2024年4月9日发出。本次会议由全体独立董事共同 推举曲新女士担任会议召集人并主持本次会议，会议应出席独立董事3名，实际 出席独立董事3名。本次会议的召集、召开和表决程序符合《上市公司独立董事 管理办法》等法律、法规、规范性文件和《乐普医疗独立董事工作制度》《公司 章程》的有关规定。全体独立董事对本次会议议案进行了审议，以记名投票表决 方式，通过如下决议： 一、审议通过《2024年度日常关联交易预计的议案》 公司2024年度预计的日常关联交易属于公司与关联方之间在生产经营中正 常的购销往来，属于正常和必要的交易行为，符合公司业务发展需要，公司与各 关联方的关联交易，严格按照关联交易定价原则执行，交易价格依据市场价格公 平、合理确定，不会对公司财务状况及经营成果产生不利影响，符合《乐普医疗 关联交 ...